EHNAC certifies first two companies for data registry

Two organizations have completed the Electronic Healthcare Network Accreditation Commission (EHNAC)'s accreditation process for its Data Registry Accreditation Program (DRAP).

The third-party review was designed in response to the privacy and security challenges of healthcare data submission and to provide an additional level of confidence for organizations that are under industry competitive pressures to demonstrate the rigor and structure of the registry database as envisioned and supported by the Centers for Medicare & Medicaid Services. 

"We're confident that the need for registries by institutional and professional providers, specialists and their trade associations, healthcare payers, federal and state governments will explode in the years ahead," said Lee Barrett, executive director of EHNAC. "To coincide with that, it is imperative to determine that the registries that are being chosen to use have the necessary protections in place to handle the many privacy and security challenges that they will face. When it comes to health data privacy and security, the risks are much too high to assume that everything is up to par--it is much better to ensure it is on the frontend by using an accredited entity that has been reviewed by a third-party."

As beta participants throughout the consultative and consensus-driven process of program development, Alpha II and FIGmd were the first to undergo evaluation on their compliance with the criteria and receive full accreditation status for the two-year timeframe.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup